Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Author's Contribution

The author read and approved the final manuscript.

Funding

None.

Conflict of Interest

None declared.

References

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(03): 209-249

[2] Feng RM, Zong YN, Cao SM, Xu RH.Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun (Lond) 2019;39(01):22

[3] Cao M, Li H, Sun D, Chen W.Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020;40(05):205-210

[4] Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3(75):75ra26

[5] Chen Y, Tang WY, Tong X, Ji H.Pathological transition as the arising mechanism for drug resistance in lung cancer. Cancer Commun (Lond) 2019;39(01):53

[6] Kimura H, Amino Y, Koba H, et al.A case of EGFR mutationpositive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment. Cancer Commun (Lond) 2019;39(01):67

[7] Mok TS,Wu YL, Ahn MJ, et al; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376(07):629-640

[8] Naumov GN, Nilsson MB, Cascone T, et al.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15(10):3484-3494

[9] Akamatsu H, Toi Y, Hayashi H, et al.Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor:West Japan Oncology Group 8715L phase 2 randomized clinical trial. JAMA Oncol 2021;7(03):386-394

[10] Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15(11):1236-1244

[11] Saito H, Fukuhara T, Furuya N, et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019;20(05):625-635

[12] Nakagawa K, Garon EB, Seto T, et al; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFRmutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(12):1655-1669

[13] Yu HA, Paz-Ares LG, Yang JC, et al.Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer. Clin Cancer Res 2021;27(04):992-1002

[14] Yu HA, Schoenfeld AJ, Makhnin A, et al.Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial. JAMA Oncol 2020;6(07):1048-1054

[15] Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-673

RIGHTS & PERMISSIONS

Global Medical Genetics